Insider Selling: Zevra Therapeutics (NASDAQ:ZVRA) CEO Sells $225,000.00 in Stock

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) CEO Neil Mcfarlane sold 20,000 shares of the firm’s stock in a transaction on Monday, October 12th. The shares were sold at an average price of $11.25, for a total transaction of $225,000.00. Following the completion of the transaction, the chief executive officer directly owned 417,225 shares of the company’s stock, valued at approximately $4,693,781.25. This trade represents a 4.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Zevra Therapeutics Stock Down 8.2%

Zevra Therapeutics stock traded down $0.93 during mid-day trading on Tuesday, reaching $10.39. 1,090,427 shares of the company’s stock traded hands, compared to its average volume of 1,257,931. The company has a market cap of $616.96 million, a price-to-earnings ratio of 11.29 and a beta of 0.98. The stock has a 50 day moving average of $11.54 and a two-hundred day moving average of $11.40. Zevra Therapeutics, Inc. has a 12-month low of $8.01 and a 12-month high of $15.03.

Zevra Therapeutics (NASDAQ:ZVRA) last released its quarterly earnings data on Wednesday, August 5th. The company reported $0.25 EPS for the quarter, beating the consensus estimate of $0.11 by $0.14. Zevra Therapeutics had a net margin of 42.82% and a return on equity of 54.54%. The business had revenue of $39.66 million during the quarter, compared to analyst estimates of $33.88 million. As a group, sell-side analysts forecast that Zevra Therapeutics, Inc. will post 0.72 earnings per share for the current year.

Analyst Ratings Changes

ZVRA has been the topic of several recent research reports. Citigroup restated an “outperform” rating on shares of Zevra Therapeutics in a research report on Thursday, August 6th. Wall Street Zen upgraded Zevra Therapeutics from a “hold” rating to a “buy” rating in a research report on Sunday, July 12th. Citizens Jmp boosted their price objective on Zevra Therapeutics from $25.00 to $28.00 and gave the stock a “market outperform” rating in a research note on Thursday, August 6th. Weiss Ratings restated a “hold (c)” rating on shares of Zevra Therapeutics in a research report on Wednesday, August 19th. Finally, William Blair upgraded Zevra Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 23rd. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $27.14.

Institutional Investors Weigh In On Zevra Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. AIGH Capital Management LLC purchased a new stake in Zevra Therapeutics in the first quarter worth $11,184,000. Hennion & Walsh Asset Management Inc. boosted its stake in shares of Zevra Therapeutics by 116.6% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 383,706 shares of the company’s stock valued at $5,502,000 after purchasing an additional 206,543 shares during the period. Dimensional Fund Advisors LP grew its holdings in shares of Zevra Therapeutics by 259.2% in the first quarter. Dimensional Fund Advisors LP now owns 554,802 shares of the company’s stock worth $5,168,000 after purchasing an additional 400,336 shares during the last quarter. Bank of New York Mellon Corp bought a new position in shares of Zevra Therapeutics in the second quarter worth about $2,846,000. Finally, Globeflex Capital L P bought a new position in shares of Zevra Therapeutics in the second quarter worth about $2,752,000. Hedge funds and other institutional investors own 35.03% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases. The company seeks to address conditions with significant unmet medical needs by combining patient-focused drug development with proprietary technologies designed to improve the delivery and development of medicines.

Zevra’s lead product is MIPLYFFA (arimoclomol), which the U.S. Food and Drug Administration approved in 2024 for the treatment of Niemann-Pick disease type C in adults and children two years of age and older, in combination with miglustat.